Journal article
Plasmodium vivax malaria serological exposure markers: Assessing the degree and implications of cross-reactivity with P. knowlesi
RJ Longley, MJ Grigg, K Schoffer, T Obadia, S Hyslop, KA Piera, N Nekkab, R Mazhari, E Takashima, T Tsuboi, M Harbers, K Tetteh, C Drakeley, CE Chitnis, J Healer, WH Tham, J Sattabongkot, MT White, DJ Cooper, GS Rajahram Show all
Cell Reports Medicine | Published : 2022
Abstract
Serological markers are a promising tool for surveillance and targeted interventions for Plasmodium vivax malaria. P. vivax is closely related to the zoonotic parasite P. knowlesi, which also infects humans. P. vivax and P. knowlesi are co-endemic across much of South East Asia, making it important to design serological markers that minimize cross-reactivity in this region. To determine the degree of IgG cross-reactivity against a panel of P. vivax serological markers, we assayed samples from human patients with P. knowlesi malaria. IgG antibody reactivity is high against P. vivax proteins with high sequence identity with their P. knowlesi ortholog. IgG reactivity peaks at 7 days post-P. kno..
View full abstractRelated Projects (3)
Grants
Awarded by Kementerian Kesihatan Malaysia
Funding Acknowledgements
We acknowledge the efforts of the original study teams for collecting the P. knowlesi clinical samples. We thank the following organisations for donation of malaria-naive control plasma: the Australian and Thai Red Cross; the Rio de Janeiro State Blood Bank (with support from Andre M. Siqueira) ; and the Volunteer Blood Donor Registry at WEHI. We thank Shazia Ruybal for support generating an automated quality control platform through R, based on prior work by Connie Li-Wai-Suen, which was also used for the standard curve con-version. We thank Sarah Miller for assistance with ethical approvals. We would like to thank the Director-General, Ministry of Health, Malaysia, for permission to publish this manuscript. We also acknowledge the Victorian State Government Operational Infrastructure Support and Australian Government NHMRC IRIISS. Funding: WEHI Innovation Fund (R.L., I.M.) . Clinical Trials Funding: Malaysian Ministry of Health (grant number BP00500420) , the Asia Pacific Malaria Elimination Network (108-07) , and the Australian National Health and Medical Research Council (NHMRC; 1037304, 1045156, 115680) . NHMRC Fellowships to N.M.A. #1135820, M.J.G. #1138860, and R.L. #1173210. NHMRC grants #1092789, #1134989, #1132975 and #1043345 (I.M.) . M.J.G. was also supported by the Australian Centre for International Agricultural Research (Grant# LS-2019-116) .